In This Article:
As you might know, SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) just kicked off its latest quarterly results with some very strong numbers. SCHOTT Pharma KGaA delivered a significant beat to revenue and earnings per share (EPS) expectations, hitting €254m-18% above indicated-and€0.31-52% above forecasts- respectively Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
View our latest analysis for SCHOTT Pharma KGaA
Taking into account the latest results, the most recent consensus for SCHOTT Pharma KGaA from ten analysts is for revenues of €1.07b in 2025. If met, it would imply a notable 13% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to accumulate 6.2% to €1.06. Before this earnings report, the analysts had been forecasting revenues of €1.07b and earnings per share (EPS) of €1.07 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
There were no changes to revenue or earnings estimates or the price target of €34.58, suggesting that the company has met expectations in its recent result. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values SCHOTT Pharma KGaA at €44.00 per share, while the most bearish prices it at €30.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of SCHOTT Pharma KGaA'shistorical trends, as the 10.0% annualised revenue growth to the end of 2025 is roughly in line with the 12% annual growth over the past three years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 11% per year. It's clear that while SCHOTT Pharma KGaA's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.